Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib + Docetaxel in Metastatic TCC
NCT00880334Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2006
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in transitional cell carcinoma (TCC), sponsored by Dana-Farber Cancer Institute. Started Sep 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT00880334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880334.